Report LibraryAll Reports
Datamonitor Healthcare Infectious Diseases Disease Analysis: HIV Pre-Exposure Prophylaxis (HIV PrEP)
August 23, 2021
Since its initial US and EU approvals for HIV pre-exposure prophylaxis (PrEP) in 2012 and 2016, respectively, Truvada’s PrEP-specific sales steadily rose to a peak in 2019, with estimated PrEP sales of $2,278m in the US and five major European markets (France, Germany, Italy, Spain, and the UK). This strong performance was driven by its status as the only approved therapy for PrEP until Descovy’s US approval in October 2019, the favorable recommendations for its use in US CDC and WHO guidelines, and reimbursement by the healthcare systems of four of the five major European markets in either national or pilot programs. However, PrEP-specific sales tumbled in 2020 to an estimated $1,281m, driven by the launch of Teva’s generic in the US market in October 2020 and rapid cannibalization by Gilead’s own successor product, Descovy.
Despite Truvada’s and Descovy’s commercial success, PrEP remains underutilized due to poor awareness and lack of/limited reimbursement in some European countries, though uptake is increasing due to recent favorable reimbursement decisions in Germany, Spain, England, Wales, and Northern Ireland, as well as Gilead’s marketing efforts. The US has the highest rate of uptake (estimated at 22% of at-risk individuals in 2020) and generates the majority of global PrEP revenues, though the October 2020 launch of generic versions of Truvada has triggered a steep decline in the drug’s sales.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||HIV Prevention|